Therefore, the present study revealed that PTN- and MIF-mediated signalling pathways play important roles in the formation of an immunosuppressive microenvironment in HER2 + IBC tumours, and therapeutic strategies targeting the corresponding pathways are expected to improve the efficacy of immunotherapy in HER2 + IBC patients. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.